Anti-CD10 (56C6) expression in soft tissue sarcomas

CD10 is known to be expressed in certain types of leukemia, in lymphomas and also in various types of carcinoma. However, data regarding CD10 expression in soft tissue sarcomas is scarce. Two hundred and two retrospective soft tissue sarcoma specimens were evaluated for CD10 expression immunohistochemically. The clinical records of these patients were reviewed, and clinical data was obtained for all patients. Our results showed that 90 of the 202 cases were found to express CD10. 72% of malignant fibrous histiocytomas, 45% of fibrosarcomas, 34% of rhabdomyosarcomas, 50% of leiomyosarcomas, 22% of liposarcomas, 72% of malignant peripheral nerve sheath tumors, and 0% of the primitive neuroectodermal tumors were positive for CD10. Nearly half of the soft tissue sarcomas were found to express CD10. Stronger CD10 expression was found in high grade sarcomas. (C) 2012 Elsevier GmbH. All rights reserved

Plasma cell granuloma of the thyroid

We report two cases of thyroidal plasma cell granuloma. Both patients underwent surgical resection after presenting with painless neck swelling. Histopathologic examination of the specimens revealed plasmacytes infiltrating the thyroid parenchyma and immunohistochemical studies showed the polyclonal nature of the plasma cells. Plasma cell granuloma is a benign lesion and its appearance in the thyroid gland is extremely rare. Eleven prior cases with thyroid localization have been reported to date in the English literature. Nine of the plasma cell granuloma cases occurred in women, four in men (including the present cases). The clinicopathologic features and diagnostic difficulties of this rare entity are described, and its relation to inflammatory pseudotumor of other sites is discussed with a review of the literature

Expression of PCNA and bcl-2 in basaloid squamous cell carcinoma of the larynx: A controlled study

We investigated the difference In the biologic nature of typical squamous cell Carcinoma (SCC) and basaloid SCC (BSCC) of the larynx by studying proliferation and antiapoptotic markers. We performed an immunohistochemical analysis of the expression of proliferating cell nuclear antigen (PCNA) and bcl-2 protein in 15 patients with laryngeal BSCC and 15 stage- and site-matched controls with typical laryngeal SCC. We found no significant difference between the two groups in the PCNA index or the frequency of bcl-2 overexpression, nor did we find and significant difference in survival. Our findings Indicate that the biologic nature of typical laryngeal SCC and laryngeal BSCC is similar. In addition, our follow-up data suggest that the clinical course of laryngeal BSCC is no worse than that of typical laryngeal SCC

Prostatic leiomyosarcoma: report of a rare case

Primary leiomyosarcoma of the prostate is extremely rare. It accounts for less than 0.1% of prostate neoplasms and has a poor prognosis. Most patients are presented with obstructive symptoms, perineal pain, burning on ejaculation, and weight loss. Multimodality treatment combinations including surgery like prostatectomy or cystoprostatectomy, preopreoperative or postoperative radiation therapy, and neoadjuvant or adjuvant chemotherapy have been used in the management of leiomyosarcomas of the prostate, but there are no standard treatment recommendations. Herein, we present a 62-year-old male suffering from recurrent hematuria and rapidly progressive prostatism, diagnosed as leiomyosarcoma of the prostate

Correlation between prenatal ultrasound and fetal autopsy findings on urinary system anomalies terminated in the second trimester

Objectiv

Prostatic leiomyosarcoma: Report of a rare case Prostatik leiomyosarkom: Nadir bir olgu sunumu

Primary leiomyosarcoma of the prostate is extremely rare. It accounts for less than 0.1% of prostate neoplasms and has a poor prognosis. Most patients are presented with obstructive symptoms, perineal pain, burning on ejaculation, and weight loss. Multimodality treatment combinations including surgery like prostatectomy or cystoprostatectomy, preopreoperative or postoperative radiation therapy, and neoadjuvant or adjuvant chemotherapy have been used in the management of leiomyosarcomas of the prostate, but there are no standard treatment recommendations. Herein, we present a 62-year-old male suffering from recurrent hematuria and rapidly progressive prostatism, diagnosed as leiomyosarcoma of the prostate